Princess Margaret Cancer Centre - University Health Network, Toronto, ON.
Sunnybrook Health Sciences Centre, Toronto, ON.
Haematologica. 2023 Jan 1;108(1):196-206. doi: 10.3324/haematol.2022.280900.
Intratumoral heterogeneity (ITH) provides the substrate for tumor evolution and treatment resistance, yet is remarkably understudied in lymphoma, due to the often limited amount of tissue that gets sampled during the routine diagnostic process, generally from a single nodal or extranodal site. Furthermore, the trajectory of how lymphoma, and especially non-Hodgkin lymphoma, spreads throughout the human body remains poorly understood. Here, we present a detailed characterization of ITH by applying whole-genome sequencing to spatially separated tumor samples harvested at the time of autopsy (n=24) and/or diagnosis (n=3) in three patients presenting with refractory B-cell non-Hodgkin lymphoma. Through deconvolution of bulk samples into clonal mixtures and inference of phylogenetic trees, we found evidence that polyclonal seeding underlies tumor dissemination in lymphoma. We identify mutation signatures associated with ancestral and descendant clones. In our series of patients with highly refractory lymphoma, the determinants of resistance were often harbored by founding clones, although there was also evidence of positive selection of driver mutations, likely under the influence of therapy. Lastly, we show that circulating tumor DNA is suitable for the detection of ancestral mutations but may miss a significant proportion of private mutations that can be detected in tissue. Our study clearly shows the existence of intricate patterns of regional and anatomical evolution that can only be disentangled through multi-regional tumor tissue profiling.
肿瘤内异质性(ITH)为肿瘤进化和治疗耐药提供了基础,但由于在常规诊断过程中通常仅从单个淋巴结或结外部位采集有限量的组织,因此在淋巴瘤中研究得很少。此外,淋巴瘤(尤其是非霍奇金淋巴瘤)在人体中的传播轨迹仍知之甚少。在这里,我们通过对在尸检时采集的空间分离的肿瘤样本(n=24)和/或诊断时采集的样本(n=3)进行全基因组测序,对 ITH 进行了详细表征,这三个患者患有难治性 B 细胞非霍奇金淋巴瘤。通过将批量样本分解为克隆混合物并推断系统发育树,我们发现证据表明多克隆播种是淋巴瘤肿瘤传播的基础。我们确定了与祖细胞和后代克隆相关的突变特征。在我们的一系列难治性高度淋巴瘤患者中,耐药的决定因素通常存在于起始克隆中,尽管也有驱动突变选择的证据,这可能是治疗的影响。最后,我们表明循环肿瘤 DNA 适合检测祖细胞突变,但可能会错过组织中可检测到的大量私有突变。我们的研究清楚地表明了区域和解剖进化的复杂模式的存在,只有通过多区域肿瘤组织分析才能理清这些模式。